AdvanCell Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Sydney NSW Australia

Primary Industry

Pharmaceuticals

About

Based in New South Wales, Australia, and founded in 2019, Advancell Isotopes Pty Ltd, also known as AdvanCell, operates as a radiopharmaceutical company. The company was founded by its CEO Andrew Adamovich. In August 2022, Advancell Isotopes Pty Ltd raised AUD 18 million in Series B funding led by Morningside Group. AdvanCell’s product line includes Alpha 212®, which is a drug that is produced with the help of targeted alpha therapy technology that is used for the treatment of cancer; ²¹²Pb, which is an alpha isotope generator platform that develops therapeutic pipeline clinical programs including ADVC001 (prostate cancer), ADVC001 (melanoma), ADVC003 (pancreatic cancer and breast cancer); and The AdvanCell ²¹²Pb Generator, which is a technology that produces alpha radioligand treatments. The company plans to use the funds raised in August 2022 to speed up the growth of its clinical program.

Current Investors

5Y Capital, Perpetual Corporate Trust Limited, AGRICO PTY LTD

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Oncology/Cancer Treatment, Specialty Pharmaceuticals, Pharmaceutical Research & Development

Website

www.advancell.com.au

Verticals

HealthTech, Manufacturing

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.